As­traZeneca’s Imfinzi stum­bles in cer­vi­cal can­cer, leav­ing Mer­ck’s Keytru­da dom­i­nant

Af­ter bring­ing As­traZeneca a steady streak of wins in re­cent months, the PD-L1 drug Imfinzi has come up emp­ty on the lat­est Phase III ef­fort.

When giv­en con­cur­rent­ly with chemother­a­py to pa­tients with lo­cal­ly ad­vanced cer­vi­cal can­cer, Imfinzi failed to hit sta­tis­ti­cal sig­nif­i­cance on im­prov­ing pro­gres­sion-free sur­vival ver­sus chemo alone, As­traZeneca re­port­ed.

That was the pri­ma­ry end­point; key sec­ondary end­points in­clud­ed over­all sur­vival and safe­ty and tol­er­a­bil­i­ty — and no ex­pect­ed side ef­fects were re­port­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER